Homology Medicines (NASDAQ:FIXX) Trading Up 7.1%

Share on StockTwits

Homology Medicines Inc (NASDAQ:FIXX) shares were up 7.1% during trading on Monday . The company traded as high as $17.18 and last traded at $17.14, approximately 421,756 shares were traded during mid-day trading. An increase of 75% from the average daily volume of 240,548 shares. The stock had previously closed at $16.00.

A number of analysts have recently commented on FIXX shares. Robert W. Baird started coverage on Homology Medicines in a research note on Monday, September 9th. They issued an “outperform” rating and a $30.00 target price on the stock. Zacks Investment Research downgraded Homology Medicines from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. FIX started coverage on Homology Medicines in a research note on Thursday, October 31st. They issued a “market perform” rating on the stock. Oppenheimer started coverage on Homology Medicines in a research report on Friday, November 1st. They set a “market perform” rating on the stock. Finally, ValuEngine downgraded Homology Medicines from a “buy” rating to a “hold” rating in a research report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Homology Medicines currently has a consensus rating of “Hold” and a consensus target price of $31.40.

The company has a market cap of $704.55 million, a PE ratio of -8.98 and a beta of 0.14. The business has a 50-day simple moving average of $13.80 and a 200-day simple moving average of $17.56.

In other Homology Medicines news, CEO Arthur Tzianabos sold 12,500 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $17.40, for a total transaction of $217,500.00. Also, CFO W Bradford Smith sold 6,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $16.21, for a total value of $97,260.00. Following the transaction, the chief financial officer now owns 6,000 shares in the company, valued at approximately $97,260. The disclosure for this sale can be found here. Insiders have sold 84,566 shares of company stock worth $1,403,999 in the last quarter. 33.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Aperio Group LLC acquired a new position in shares of Homology Medicines during the second quarter valued at approximately $34,000. Bank of Montreal Can acquired a new position in shares of Homology Medicines during the second quarter valued at approximately $40,000. Cubist Systematic Strategies LLC acquired a new position in shares of Homology Medicines during the second quarter valued at approximately $42,000. Marshall Wace LLP acquired a new position in shares of Homology Medicines during the first quarter valued at approximately $74,000. Finally, Royal Bank of Canada raised its holdings in shares of Homology Medicines by 300.0% during the second quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock valued at $78,000 after acquiring an additional 3,000 shares during the last quarter. Institutional investors own 71.06% of the company’s stock.

About Homology Medicines (NASDAQ:FIXX)

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Article: How accurate is the Rule of 72?

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates Q1 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates Q1 2020 Pre-Market Earnings Guidance
Express  Issues Q4 2019
Pre-Market Earnings Guidance
Express Issues Q4 2019 Pre-Market Earnings Guidance
Applied Industrial Technologies  Releases FY20 Earnings Guidance
Applied Industrial Technologies Releases FY20 Earnings Guidance
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.


© 2006-2020 Ticker Report